Interim report
Page 1
IS/ISO 9001 : 2000 General Office : "Ali Towers" Ill Floor, #55, Greams Road, Chennai - 600 006. Regd. Office : 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. The unaudited financial results will be published in the newspapers in accordance with Regulation 47 of the SEBI (Listing Obligation s and Disclosure Requireme nts) Regulations, 2015 ("SEBI Listing Regulations"). The said financ ial results, which have been subjected to limited review by the Statutory Auditors of the Company, toget her with the Limited Review Reports thereo n, are enclosed as Annexure A. The Board approved the unaudite d standa lone and consolidate d financial results of the Company for the three and six months ended 30 September 2026. 1. Unaudited Financial Results The Board of Directors of the Company, at its meeting held today, inter alia, considered and approved/took note of the follow ing matte rs: We refer to our letter s dated 24 Septem ber 2026 and 12 October 2026 regarding the captioned subjec t. Sub: Outcome of the Board Meeting Dear Sir/ Madam, The Secretary, National Stock Exchange, Exchange Plaza, 5th Floor Plot No.C/ 1, 'G' Block Sandra - Kurla Complex Sandr a (E) Mumbai - 400 051. Scrip Code- APOLLOHOSP ISIN INE437A01024 The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumb ai - 400 001. Scrip Code - 508869 ISIN INE437A0 1024 November 4, 2026 CIN: L85110TN1979PLC008035 ~ IT A"jibllo P osPITALS APOLLO HOSPITALS ENTERPRISE LIMITED
Page 2
Tel : 044 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohospi Website : www.apollohospitals.com General Office : "Al i Towers" Ill Floor, #55, Greams Road. Chennai - 600 006. Regd. Office : 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. IS/ISO 9001 : 2000 Dr. Ritu Garg, Chief Executive Officer, Multi Regions (North, Cent ral, Western and Eastern Regions). She has over two decades of healthcar e experie nce, she brings ext ensive experti se in operat ions, growth, tran sformat ion and innovation. A clinician by tra ining, she holds an MBBS, MS and an MBA in Finance & Strateg y. In line with the Compan y's leadership strengthening initiatives and to ensure seam less business continuit y, based on the recommen dation of the Nomination and Remuneration Committ ee, the Boar d of Directors designated the followin g personnel as Senior Management Personnel of the Compan y: Leadership Talent Addition During his tenure with the Company, Dr. Madhu Sasidhar made significant contri butions tow ards streng thening clinical excellence practices and in augmenti ng the Company 's digital health capabilities . There is no material reason for the cessat ion of his office other than the reason stat ed above. 2. Changes in Senior Managemen t Personnel In terms of Regulation 30 of the SEBI Listing Regulati ons, read with the applicable SEBI Master Circular , as amended from time to time, we wish to inform you that Dr. Madhu Sasidha r, a designated Senior Managerial Personnel (SMP) of the Compa ny, will cease to hold the position of President & CEO - Hospitals Division, effecti ve from the closure of business hours on November 14, 2026 consequent to the successful compl etion of his emp loyment tenur e. The financ ial results and the Limite d Review Reports will also be made available on the Company's webs ite at www .apollohospit als.com. CIN: L85110TN1979PLC008035 ' IT (Aollo ~ OSPITALS APOLLO HOSPITALS ENTERPRISE LIMITED
Page 3
';'.el - ,,_,.:'~ ~4 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohospi Website : www.apollohospitals.com General Office : " Ali Towers" Ill Floor, #55, Greams Road, Chennai - 600 006. Regd. Office : 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. The Company had earlier informed the Stock Exchanges that, at its meeting held on 20 May 2026, the Board had approved the divestme nt by Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company , of its entire shareholding in Apollo Specialty Hospitals Private Limited ("ASHPL") and Apollo Ferti lity Centre Private Limited ("AFCPL") to Kids Clinic India Limited ("KCI L"), which operates under the brand name "Cloudnine" . .,,. 1-~ ,;~ IS/ISO 9001 : 2000 ({I 1• 3. Complet ion of Divestme nt by Apollo Health and Lifestyle Limited in Apollo Specialty Hospitals Priva te Limited and Apollo Fert ility Centre Private Limited as well as receip t of consideration and allotment of securities repre sent ing an effective 9.9% equity stake in Kids Clin ic India Limited Annexure C - Details of designation of Senior Management Personnel. Annexure B - Cessation of Dr. Madhu Sasidhar as President & CEO - Hospitals Division and SMP of the Company; and The requisite disclosures in relation to the above, as required under the SEBI Listing Regulations and applicable SEBI circulars, are enclosed as follo ws: The support functions & other regions previo usly reporting to the President & CEO will report to the Project Management Office under the guidance of the Managing Director . Dr. N. Venka tesan, Chief Procurement Officer . He has over 25 years of diverse experience across healthcare procurement, supply chain, pharmacy operations, materials management, comme rcial functions and hospital projec t execution. He holds a Ph.D. in Hospital Supply Chain Management and an MBA in Systems. Mr. Anand Wasker , Chief Business Officer - International. He has over 26 years of leadership experience building, scaling and trans forming large service businesses across healthcare, financial services, telecom, education, beauty and wellness consumer services. He holds a Master 's degree in Business Management. CIN: L85110TN1979PLC008035 ' 11' (Aollo ~ OSPITALS APOLLO HOSPITALS ENTERPRISE LIMITED
Page 4
Tel : 044 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohospi Website : www .apollohospitals.com General Office : "Ali Towers" Ill Floor, #55. Greams Road. Chennai - 600 006. Regd. Office : 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. IS/ISO 9001 : 2000 Yours faithf ully For APOLLO HOSPITALS ENTERPRISE LIMITED Thanking you, The above inform ation is also being made available on the Company's website at www .apolloho spitals.com Kindly take the above informatio n on record. 5',35"' The Board Meeting commenced today at 3.20 p.m and concluded at ....... p.m. Consequently, ASHPL and AFCPL have ceased to be subsidiaries of AHLL. We wish to further inform you that tran saction closure has been fully ensured on 3rd November 2026. AHLL has received the agreed consideration and has been allotted securities in KCIL represen ting an effecti ve equit y stake of approximate ly 9.9%. The transaction was envisaged at an enterprise value of approximatel y ns,soo million, comprising cash considerat ion of ~7,650 mill ion and an effective equity stake of appro ximately 9.9% in KCIL, valued at n ,850 milli on. CIN: L85110TN1979PLC008035 IT (Aollo ~ OSPITALS APOLLO HOSPITALS ENTERPRISE LIMITED
Page 5
• Not annualised Foot note: 1 rne Comp any has presented EBJTDA addlhonally as part ot standalone financial results. Thr ee months Prcccc ding three Corr esp ondin g Ycil r to date figu res Year to dat e figures Parti cul ars ended mo nths ended three mon th s for current perio d for previous period Prev ious ye ar 30 / 09 / 2026 30/ 06/ 202 6 ended ended 30/ 09/ 2026 ended 30/09/ 202 5 ende d 31/ 03/ 202 6 30 / 09/20 25 Unaudrted Uneudrted Unauc11tt!<I Uni1ud1t..,,.cJ rj nau drted Audited I Income (a) Revenue from operations 2q,02q 26,561 23,561 55,590 45,240 q3,262 ( b) Other income 1,114 471 1.411 1.585 I, 736 3 718 Toto! inc ome(• + b) 30,143 27,0 32 24 ,972 57, 175 46,976 96,980 2 Expenses (a) Cost of materials consumed 7,299 6,671 6, 112 1),970 12,009 2•1, 188 (b) Employee benefits expense 5,) 01 4,58) 4,) 12 9.885 8,349 16,86 2 (c) F1nanc1? costs 712 683 579 l,395 I, 167 2,417 (d) Oepreo ono n and amorusauo n expenses 1,410 1,)4 3 l,22'1 2,753 2,45 6 5,004 (c ) Other expenses 9,203 8,7-15 7.208 17,947 13,492 28.932 Total exp enses 23 ,92 5 22,025 19,435 45,95 0 37,4 73 77,403 3 Pront befor e tax ilnd exc ep ttcrm t item s ( 1) • ( 2) 6,218 5,00 7 5,5 37 11.225 9,50 3 19,577 4 Exceptional item (Refer note 7) ( 114) 5 Pr ofit befor e tax (3) + (4 ) 6,218 5 007 5,537 11,225 9,503 19,463 6 Tax expens e Current tax 1,538 l,2'16 l,232 2,785 2, 125 4,573 Deferred l->x 1771 (91) 106 1167) 110 (3 6) 7 Profit aft er ta x for the period I year ( 5) - ( 6) 4 757 3 85 2 4 199 8 607 7 268 14,926 8 Oth er comprehensive inc ome/ (loss) Ur.ms that will not be rcclass,fic d to profit or loss (a) Remeasurement gains/( losses) on defined benefit plans (116) 45 (108) (7 l J (32 ) ( 142) {bl Net change in fair valuc or investment s in equity instru ments measured at fair value (10) (c) Income tax relat ing to items that will not be reclassified to profit or loss 29 (II ) 27 18 8 36 Tota l oth er compre hensive inc om e/ (loss) (87) ) 4 1811 (53) 124) (116) 9 Total comprehen siv e income fo r th e period / year (7) + (8) 4,67 0 3,886 4,118 8,554 7,244 14,810 10 Paid-up equi t y share capital (Face volue Rs. 5/· per share) 719 719 719 11 Reserves (excluding revaluation reserves) L.06,381 92,430 98,913 12 Earning s pe r equity share ('EPS') of Rs .5/- each 8asJc EPS for the period/ year (Rs.) 'J) .08 ·26.79 '29.20 '5 9.86 -so.ss 103.81 Dilut ed EPS for th e period/ year (Rs.) ") 3.06 '26.78 • 29.20 "59.82 -so.ss 10) .74 13 Ad dit1ona1 I nformation :- Earn ings befor e fi nance costs , ta x, depre ciat ion and amorti zation, other 7,226 6,562 5,929 13,78 8 11,390 23,280 incom e, exceptional ite ms ( EBIT OA) (re fer foo t note) (Rs in Milli on) Apoll o Hosp ita ls Ent erpris e Lim ite d Corporate Identity Numbe r: L8S 110TN 1979 PLC00803S Regel. o n.cc ; No. 19 Bishop Gardens. Rt1J.J Annamala,pur.im, u ,cnna, • 2~. f c1m11 N11du Tel No. 44·2tJl 90956. Fa.(+- 91··14-282 909SG, Emi:\11 : 1n·,cs to r.rcl,1tionc;J)r1pollohosp1tcJls.com Website· www .,.:,pollohu,;p1tJ1s.com Sta teme nt of Stand alone un audit e d Financi al Res ult s fo r the thr e e m ont hs and six m onths ended Se pte mb er JO , 2026
Page 6
Managing Director (Rs. in Million) As at As at Partic ulars 30-Se o-26 31-Ma r- 26 Unudit ed Audited ASSETS Non-curr ent asset s (a) Prooert v. olant and eauioment 56.44 8 54.45 2 (b) Right -of -use assets 13,693 13,767 ( c) Capital work-in-progr ess 5,491 3,015 ( d) Other intangi ble assets 745 945 (e) Intangible assets under development 228 182 ( f) Financial assets (i) Investments 38,789 38,76 9 (ii) Loans 6,599 5.589 (iii) Othe r financial assets 1,511 1,73 0 (g) Income tax asset (net) 87 376 ( h) Other non-current assets 1 793 1 816 Tota l non-current ass et s 1,25,384 1,20 ,640 Curr ent assets (a) Inventories 1,726 1,468 (b) Financial assets (i) In vestments 8,914 10,158 (ii) Trade receivables 10,493 8,473 (iii) Cash and cash equivalents 2,767 3,42 6 (iv) Bank balances other than (iii) above 2,827 61 (v) Loans 565 753 (vi) Other financial assets 1,989 1,372 ( c) Contr act assets 1,189 1,013 ( d) Other curr ent assets l 978 1 780 Tota l current asset s 32,448 28 ,504 Tot al asse ts 1 57 832 149 144 EQUI TY AND LIABILITIE S Equity (a) Equity share capital 719 719 (b) Other equity 1 06 381 98.913 Tota l equity 1,07 ,100 99 ,632 Liabilitie s Non-current li abiliti es (a) F inancial liabilities (i) Borrow ings 15,281 16,250 (ii) Lease liabilities 12,919 13,257 (iii) Othe r fina ncial liabilit ies so 18 (b) Deferred tax liabilities (net) 3,375 3,560 ( c) Other non-curren t liabilities - 12 Tot al non-c urre nt liabiliti es 31,625 33,097 Curr ent liab ili ties (a) Financial l iabilities (i) Borrowin gs 1,964 1,972 (ii) Lease liabilities 615 416 (ii) Tr ade payab les (a) Total outstand ing dues of micro ent erprises and small 731 968 ent erori ses; and (b) Total outstanding dues of creditor s other than micro 10,90 3 8,589 enterp rises and small ente rorises (iv) Other financial liabilit ies 2,353 1,598 (b) Other curr ent liabilities 1,763 1,785 ( c) Provisions 778 1 087 Tot al cur rent li abi lit ies 19,107 16,415 Tot al liabi lities 50,7 32 49,5 12 Tot al eauitv and liabilitie s 1 57 832 1.4 9 144 Standa lone Balance Shee t Apollo Hospitals Enterprise Limited Corpor at e Ident ity Numb er: L85110 TN1979 PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956, Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com Website: www.apollohospitals.com Annexure -I
Page 7
UNEETA R.Eo~ C Managing Director i-or At'ULLU MU.>r I l~L;:) i:;;1~ c"r"l..;)I;; LIU - 1,044 (819) (577} (977) (930) (774) (777) (1,438} (l ,438) (4,00 8) (2,678 } (659) (774) 3,42 6 2,33 2 2,767 1,558 73 64 2,694 1,494 2,767 1,558 c. Cash flow fro m financing act ivities Proceeds from borrowings Payments towards lease liability Repayment of borrowings Finance costs Dividends paid Net cash used in fin ancing act iv it ies ( C) Net Increase/( decrease) in cash and cash equivalents (A+B+C) = (D) Cash and cash equi valents at t he beginn ing of th e period (E) Cash and cash equi valent s at th e end of t he period (D} +(E) Cash and cash equ iv alent s compr ise s of - Cash on hand - Balance with banks Total cash and cash equivalents at the end of the period Cash generated fr om operati ons Net income tax paid Net cash generat ed fr om op erati ng act ivit ies (A) B. Cash flow fr om investing Act iviti es Purchase of Property, plant and equipm ent, capital work-in-progress and intangibles Proceeds from sale of property, plant and equipment Loans given Repayments received towards loans Purchase of non-current investme nts Purchase of current investm ents Proceeds from sale of current investm ents Proceeds from/(Invest ment in) bank deposits Interest received Dividend received from subsidiaries and associates Net cash used in investing activities (B) Adj ustment s fo r incr ease/ (decreas e) in op erati ng liabilit ies Trade payables Other financial liabilit ies Provisions ot her liabilities Oper at ing Profit befo re w orking capital changes Adju st ments fo r (increase)/ dec rease in op erat ing asset s Inventories Trade receivables Other financial assets Other assets A. Cash flow fr om Opera t ing Activ ities Profit fo r t he period Ad j ustm ent s f or: Depreciation and amortisation expenses Income Tax expense ( Profit)/ loss on sale of property plant & equipment Profit on sale of investmen ts (net) Gain on fair valuation of mutua l funds Gain on fair valuation of equity investment s Finance costs Interest from banks/o thers Dividend on non-current equity investments Expect ed credit loss on trade receivables Unrealised foreign exchange (gain)/ loss (net) Provisio n written back Share based oavment exoense PARTIC ULARS (Rs in Milli on) For t he period ended For th e period ended Sept emb er 30 , 20 26 Sept ember 30, 2025 8,607 7,268 2,753 2,456 2,617 2,23 5 29 (31) (79) (81) (261) (525) (4) (1) 1,395 1,167 (46 0) (428) (718) (900) 305 222 (3) 9 (4) - 312 - 14,489 11,391 (258) (67) (2,324) (1,44 1) (457) (173) (210) 316 (3, 2491 (1,36 5} 2,08 0 855 698 353 (375) 89 (33\ 166 2,370 1,463 13 ,610 11,48 9 (2,495) (2,051) 11 ,115 9,43 8 (6,655) (3,42 2) 11 98 (1,671) (l ,022) 849 8 (30) (444) (8,051) (9,508 ) 9,649 5,644 (2,727) 108 141 104 718 900 (7,766) (7,534 } Apollo Hospitals Enter prise Limited Cor porate Id enti ty Numb er: L85110 TN1979 PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956 , Fax+ 91-44-282 909 56, Email : investor.relations@apollohos pitals.com Website: www.apollohospitals.com St atement of St andalone Cash Flow s Annexure-II
Page 8
ForAPO~ NTERPRISE LTD SUNEETARlf Managing Director Nation al Stock Exchange of India Limit ed and Bombay Stock Exchange Limited have issued letters dated December 23,202 5 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligat ions and Disclosure Requirem ents) Regulatio ns, 2015. Based on the directio ns of the Hon'ble Company Law Tribunal, meeti ngs of the Secured Creditors, Unsecured Creditors and the Equity Shareholders of the Comp any were convened on June 24, 2026 with requisite approvals being obtained for implementation of the Scheme and statu s being updated to the Company Law Tribuna l. Subsequent to the receipt of such approv als, the Compan y has filed a petition before the Natio nal Company Law T ribunal seeking sanction of the scheme. The Scheme inter alia provide s for demerger of identified business undertaking (as defined in the scheme) primarily repr esenting the Omni channel pharmacy distr ibution business and digital health platfor m business of the Company into the Result ant Company; the amalgamation of "Transferor Company 1" wit h and into the Resultant Company; the a malgamat ion of "Transferor Company 2" with and int o the Resultant Company; and the consequent listing o f the equit y shares of the Resultant Company on the National Stock Exchange of India Limit ed and Bombay Stock Exchange Limited and admi ssion to trading. 4. The Board at its meeting held on June 30, 2025 , subject to necessary appr ovals considered and approved a Composite Scheme o f Arra ngement amongst , the Company (AHEL), Apollo Healt hco Limited ("T ransferor Compan y 1" or "AHL") - Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholder s and credito rs ("Scheme"), in accordance with the provi sions of Sections 230-232 and other applicable prov isions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circula r dated June 20, 2023 (SEBI/ HO/ CFD/ POD- 2/P/ CIR/2023/93) , and other applicable rules, regulations, and circulars issued by regulatory authoritie s. 3. The Company 's business activity primarily falls within a single reportable b usiness segment namely "Healthcare Service s" and operates primarily in India and accordingl y does not have any additiona l disclosure to be made under Ind AS 108- "Segment Reporting ". 2. The standalone unaudit ed financial results have been prepared in accorda nce with the Indian Accounting Standa rds ("Ind AS") as prescribed under Section 133 of the Comp anies Act, 2013 ("the Act") read with relevant rules issued thereunde r and in terms of Regulat ion 33 of SEBI (Listing Obligatio n and Disclosur e requirement s) Regulations, 2015. 1. The standa lone unaudited financial results ("t he statement") of Apollo Hospitals Enterp rise Limited ("the Company") for the three and six months ended September 30, 2026 have been reviewed by the Audit Comm ittee and a pproved by the Board of Directo rs of the Company at their meetings held on November 3, 2026 and November 4, 2026 respectively. The statuto ry auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three and six mo nths ended September 30, 2026. NOTES TO THE STANDALONE UNAUDITED FINANCIAL RESULTS: Apollo Hospitals Enterprise Limited Corporate Identity Number: L85110TN1979PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956, Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com Website: www.apollohospitals.com
Page 9
Dr. Prath ap C Reddy Execut ive Chair man Place: Chennai Date: November 4, 2026 For APOLLO HOSPITAL S ENTERPRISE LIMITED 9. The aforesaid unaudit ed financial results are a lso available on the Company's website (www. apolloho spitals.com). 8. The standalone balance sheet as at September 30, 2026 and the statement of Cash flows for the six months ended September 30, 202 6 are prov ided as annexure to this statement. The Company has assessed the financia l implication s of these changes, which has result ed in incre ase in gr atuit y liabilit y arising out of past service cost and increase in leave liability by Rs. 114 milli on for the year ended March 31, 2026. Considering the materiality and regulator y driven non-recurrin g nat ure of this impact, the Company has presented the same as Except ional item in the Stateme nt, The Company cont inues to monitor the finalisation Of Central and State Rules, as well as Governm ent clarifi cations on other aspects of the Labour Codes, and will incorporate appropriat e accounting tr eatm ent based on these developmen ts as required. 7. On November 21, 2025 , the Government of Indi a notifi ed prov isions of the Code on Wages, 2019 , the Indu strial Relations Code, 2020, the Code on Social Securit y, 2020 and the Occupationa l Safet y, Health and Work ing Condit ions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing emplo yee benefits during employment and post employment. 6. The The Board of Director s in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospital s Nort h Limite d, a wholly owned subsidiary with the Comp any. 5. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each part y shall: (i) independently pursue its respective businesses; and (ii) collab orate and cooperate with the other for mutu al benefit . Upon effect iveness of the Scheme, the right s and obligation s of AHL under this agreement will be bindin g on the Resultan t Company . Apollo Hospitals Enterprise Limited Corporate Identity Number : L85110TN1979PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956, Fax+ 91-44-28 2 90956, Email : investor .relations@apollohospit als.com Website: www.apollohospita ls.com
Page 10
Regd. Office: One International Center, Tower 3, 31st floor, Senapati Ba pat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 ../'---'" - "'"\ . , Nachiappan Subramanian Partner Membership No. 218727 UDIN: 26218727KWSWEA5267 Place: Chennai Date: November 4, 2026 For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018) TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Apollo Hospitals Enterprise Limited ("the Company"), for the three months and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS Tel: +91 44 6688 5000 Chartered Accountants ASV Ramana Tower 52, Venkatnarayana Road T. Nagar Chennai-600 017 Tamil Nadu, India Deloitte Haskins & Sells LLP
Page 11
For APOLLO Hv::;;r\SE LTD SUNEETAREDDY ~ Managing Director Unaud ited Unaud ited Audited 1,45,468 J,19.236 2,47,737 927 943 1 870 l 46 395 1 20 179 2 49 607 17,502 14,920 29,889 58,268 47,802 1,00,56 4 (423 ) (78) (21 6) 16.502 l4,4<i6 29,286 2,221 l. 958 3,996 4,526 4,072 8,260 30 941 24 557 51 368 1 29 53 7 1 07 67 7 2 23 147 16,858 12, 50 2 26,460 253 199 ,.9 17 111 12 70 1 26 90 9 l 192~ 17,111 12 ,701 26, 717 4,645 2,863 6,279 (3121 361 289 L2.778 a 47 7 20.149 141) (127) (108) 38 14 79 (127 122 12 699 9 35 0 20 027 (69) (31) (116) 745 735 17 (98) (64) 11 29 (47) 627 584 12 65 2 9 977 20 611 12,106 9,100 19,417 593 250 610 (47} 625 577 0 7 12.059 9.72 5 19.994 593 252 617 719 719 719 1,05,245 90,136 94,004 "84,74 '63.90 135.63 •94,59 "63,90 135 .53 '(0.55) '(0.61) '(0.59) -to.ssi '(0.61) '(0.59) •43,7d '41.01 '33.51 '43.71 "41.00 0 33.5 1 '0.08 '(0 .63) '(0.31) '0.08 '(0 .63) '(0.31) 5,337 171 565 4.772 168 5 50 8 568 11 (92) 745 (96) 4 940 66 (66) 5 006 1,615 192 6,813 6 81 3 63 6,750 55 683 7,659 24,647 2 7,490 986 2,053 12 846 62 433 545 61,868 Unaudited Thr ee month s Pr eceding thre e ended month s end ed J0/09 / 2026 30 / 06/2026 Unaudi ted Unaudit ed 76,149 69,319 448 479 76 597 69 79 8 9,352 8,150 30.590 27,678 (426 ) 3 8,732 7,7i 0 1,1.JO 1,081 2,302 2,224 15 993 14 948 67 683 61 854 8,914 7,944 119 134 9 033 8 078 9,033 8,07 8 2,542 2,103 (93 {219) 6 .. . . ... 49 (90) l R 11 90 6 595 6 104 (109) 40 19 (2) 86 39 6 509 6 14 3 6.299 5,807 296 297 (8 7) 40 (I) 6.212 5,8d7 297 296 "Not annualised From discontinued oper ation s BaS1c EPS for the penod/vear (Rs.) Diluted EPS for the period/year (Rs.) Fro m co nti nuin g op er ati ons Basic EPS for th e period/y ear (Rs.) D!luted EPS for the period / year (Rs.) 15 Earn ings per equity share ('EPS ') of Rs.S/ - eec n 1"l Paid-up equlty shar e captter (Face value Rs.SJ- per share) Reserve s (exduding reva lu ation re serv es) Total compr ehen sive incom e fo r t he period/ y ear att ributabl e to: Owners of the parent Non·contro l111"19 mte rest Oth er comp rehen siv e income/ (to ss) fo r th e peri od/ ye ar att ributabl e to: Owne r s of th e parent Non•contro ll,ng interest Profit fo r the period/ y ear att ributable to: Owners of the parent Non•contr olling interes t To tal oth er co mp rehensiv e income / (loss) 13 Total c ompr ehensive Inco me fo r th e period/ ye ar (11) + (12 ) 12 Oth er Compreh ensiv e Income Items that will not be rcdassif ied to profit or lo ss Remeasureme nt qalns / (losses) on defined benefit plan Equ,ty instruments lhrough other comprehens ive income lncom e tax rela!lng to Items that wllt not be redasslfled to profJt or loss Items that will be rcclasslflc d to profit or loss Exchange diffe r ences In translati ng the flna nclal stateme nts of foreign opera tions 11 Pr ofit aft er tax fo r the oerio d/ vea r (9) + l 10) a} ProfitJ (los..<.) before tax for the penod/ye,:,r from discontinue d operation s b) Taic exoenses/l benenn of discontin ued coerartoos 10 Pr ofit arter tax f or the oer iod/ ve c1r fr om disco ntinued ooeratlon s Disc ont inued Ooer atlons (Refer Note 8) 2 Expenses (a) Cost of materials consume<! (b) Purchases of stoct.c-,n·tra de (c) Changes In inventor ies of stcck-te-uaoc (d) £;mployce benefits expense {e) Finance costs (I) neoreoanc n and amortlsaUon excense (g) Other expenses Tot al exp enses 3 Profit befo re share of pro fit/Cl oss ) in associat es I j oi nt v ent ur es and exce pti onal Item s (1) - (2) 4 Share of profiU( loss) of esseeretes /joi nt ventures 5 Profit befor e tax an d exeee uenat It ems fr om contlnulnQ eeerettcns (3) + f4 ) 6 Except ional Item (Refer note 6} 7 Profit befo re tax fr om co ntinuin g oper ati ons (5) + (6 ) 8 Tax expen ses Current tax Deferred ta x 9 Pr ofit aft er tax for th e oe rlod / vear fr om continui nq ooer atlons (7l - f8 l 1 In come (a) Revenue from ecercncns (b) Other income To tal rnec m e (a + b) Continuing Operations (Rs. In Mllllon l Stat em ent of unaudit ed consolidat ed f inancial results for th e th ree months and six month s ended Septem ber JO, 202 6 Part iculars Apoll o Hospita ls Ent erpri se Limit ed Corpo rate Identity Number : L851 10TN1979P LC0080 35 Regd. Otnce : No. 19 Bishop Gardens, Rag 1 Annamalal puram, Chennat • 28, Tamll Nadu Tel No, 44·28290956, Fax+ 91· 44·282 90956, Email : investo r.r~a t1ons@lapollohosp1tals.com Website: www.apollohosp itals.com
Page 12
r or APULDJ , ·~~· r "kJY SUNEETA~ - ~ Managing Director 2 21 96 9 ·- --· - · 1 l' .- ., 1TC:ODOIC C: Tl 1 '.142 222 Tot al eauitv and liab ilit ies 1,22,224 1,30 ,651 64 ,813 76,251 1,226 21,292 3,310 3,081 1.953 26 1,080 26, 497 3.800 3,068 1.736 9 7,049 32,28 4 1,641 31,46 1 1,551 57.411 54 .400 24,301 26,703 300 995 4,982 130 24,4 87 23,994 341 760 4.685 133 99 ,745 1,11,571 94,8 01 4 944 1,06,042 5 529 719 94 082 719 1 05 323 Tot al liabiliti es Curr ent liabiliti es (a) Financial liabilitie s (i) Borr owings (ii) Lease liabil ities (iii) Trade payables (a) Tota l outstand ing dues to micro enterp rises and small enterpr ises; and (b) Total outstanding dues to creditors other than micro enterpr ises and small enterprises (iv) Other finan cial liabilities (bl Other curren t liabilit ies ( c) Provisions (d) Current tax liabilities (net) Liabili ties directly associated with assets classified as held for sale Total current liabilities Liabilit ies Non -c urr ent liabllit ies (a) Financia l liabilities (i) Borrowinqs (ii) Lease liabilities (iii) Othe r financi al liabilities ( b) Provisions (c) Deferred tax liabilities (net) (d) Other non-current liabilit ies Tot al non -curr ent Liabi liti es Non·controllino interes ts Total equity Equity attr ibutable to owner s of the Comoany Equity (a) Equity share caoital (b) Other equity EQUITY AND LIA BIL I TIES Tota l asset s Current assets (a) Inventor ies (b) Financial assets (I) Investments (Ii) Trade receiv ables (iii) Cash and cash equivalents (Iv) Bank balances other than (ii i) above (v) Loans (vi) Other financial assets (c) Cont ract assets (d) Other cur rent assets Assets held for sale Tot al cur re nt asset s ASSETS Non-curr ent assets (a) Procertv, olant and ecuicment (bl Riqht Of use assets (c) Capita l work-tn-proqress ( d) Inv estment oropertv (e) Goodwill (fl Other intanoible assets (o) Intanoib le assets under develooment (h) Investments accounted for usinq the equity method (i) Financial assets (i) Investme nts (II) Loans (iii) Other financial assets (1) Defer red tax assets (net) (kl Income tax assets (net) (I) Other non- curre nt assets Total non-curr ent asset s Parti cular s (Rs in Mill ion ) As at As at 5eo tember 30, 2026 Mar ch 31 2026 Unaudited Audit ed 84,068 82.586 25,96 4 27,800 14,939 9,915 19 22 10,300 10,323 1.675 1,985 433 409 2,739 2,564 9,075 9,058 23 156 2,544 3,530 138 141 1.442 1.961 3 182 2 521 1,56,541 1,52 ,971 6,234 5.424 10,103 10,165 42,562 34,849 5,874 8,113 7.834 3.055 106 24 1.767 2.086 2.076 1.862 3,819 3,420 5,306 85,681 68 ,99 8 2 42 222 2 21 969 Con solidate d balance shee t Apollo Hospitals Enterprise Limited Corpo rat e Id entity Number: L85110TN 1979PLC0080 35 Regd. Office : No. 19 Bishop Gardens, Raja Annam alaipuram, Chenn ai • 28, Tamil Nadu Tel No. 44·28290956, Fax+ 91·4 4-282 90956, Email : investor.r elations @apollohospitals.co m Website: www .apollohospita ls.com Annexu re I
Page 13
For APOLLO HO~Plu Rf:7 SUNZ~ EDDY v Managing Director "The Company has allocated the entire assets and liabiliti es on a reasonable basis to Its existing segments in line with the revised method used by the company to present segment information to Its chief operating decision makers. Consequently, the Company has also re-presented the previo usly report ed unallocated segment assets and liabilities to the existing segments in line with the revised method of allocat ion:· IRs. in Million ) Corresponding Year to dat e Year to date Three mo nths Prec edin g three three months figu res for curr ent figur es for Prev ious year Particulars end ed month s ended ended per iod ended previous period ended 30 / 09 / 2026 30/ 06 / 202 6 30/ 09/ 2025 30/ 09 / 2026 ended 31/ 03/ 2026 30 / 09 / 2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited ! .Segme nt reve nue a) Healthcare services 39,630 36,101 32,136 75,731 61,804 1,27,238 b) Retail health and diagnostics 4,293 3,879 3,592 8,172 6,870 14,104 c) Digital health and pharmacy distribution 32,858 29, 770 26,605 62,628 51,324 1,08, 081 dl Others 64 107 so 171 133 316 SUB - TOTAL 76 845 69 85 7 62 383 1 46 702 1 20 131 2 49 739 Less : Jnterseamental revenue 696 538 495 1,234 895 2 002 Reven ue from ooeratlo ns 76 149 69 319 61 888 1 45 468 1 19 236 2 47 737 2. Segment results a) Healthc are servic es 7,600 6,844 6,319 14,444 11,956 24,364 b) Retail health & diagnosti cs 380 211 108 591 143 416 c) Digital health & pharmacy distrib ution 1,728 1.523 859 3,251 1,551 3,987 d) Others 1102) (32) (95) (134) (133) (181) SUB· TOTAL 9 606 8 546 7 191 18 152 13 517 28 586 Less: (I) Finance cost (1,140) (1,081) (98 6) (2,221) (1,958) (3,996 ) Add: (ii) Other un-auocabte Income, (net of expenditu re) 448 479 545 927 943 1,870 Add: (Iii) Share of profit /(loss) of associates/ joint ventures 119 134 63 253 199 449 Less: (iv) Exceptional item (Refer note 6) . . (192) 3. Profit befor e tax fro m contlnuina ooer atlons 9 033 8 078 6 813 17 111 12 701 26 717 4. Profit before tax from discont inued ooerati ons (Refer Note 8) 49 (90) (6 6) (41) (127 1 11081 5. Pro fit befor e ta x· 13\ + 14\ 9 082 7 98 8 6 747 17 070 12 574 26 609 a) Healthc are service s Seomen t asset s 1,77,544 1,71,434 1,62,276 1,77,544 l ,62,2 76 1.63,075 Seoment hebitiues (62,697) (60,457) (58,046) (62,697) (58,046) (57,348) b) Ret ail health and diagno stics Segm ent assets 11,579 16,201 15,6 98 11,579 15,698 15,959 Segment liabilities (14,948) (21,545) (21,294) (14,948) (21,294) (21,383) c) Reta il hea lth and dl agnostics·D iscontin ued operatio ns (Refer Note 81 Seqment assets 5,306 5,306 Seqment liabilities (7,04 9) (7,0 49) d} Digi t al health and pharmacy dist ributi on Segment assets 46,24 1 42,972 40,277 46,24 1 40,277 41,493 Segment liabilit ies (44,03 5) (42,168) (43,152) (44,035 ) (43,152) (41,805) e) Oth ers Seqment assets 1,552 1,504 1,249 1,552 1,249 1,442 Segment liabilities (1,921) (1,778) (1,474) (1,921) (1,474) (1,689) Tota l 1,11,57 1 1,06,162 95,534 1,11,571 95,534 99,745 Consol idated Segment wise revenue , resu lts, segme nt assets and segment liabiliti es Apollo Hospita ls Enterp rise Limited Corp orate I dentity Number: L85 110 TN1979 PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalai puram, Chennai • 28, Tamil Nadu Tel No. 44·2 8290956, Fax+ 91·44·282 90956, Email : investor.relations@apollohospitals.com Website: www.apollohospitals.com Annexure I I
Page 14
For the period ended Septem ber 30, 2025 For t he per iod ended Sept em ber 30 , 20 26 Partic ulars 90 (154) 30 419 (9) (412) Net cash generated from operati ng ectivit tes Net cash generated/{u sed) in investing acnvme s Net cash generated/(u sed) 1n financing acnvrt tes Net cashfl ows attrib ut able to disc ont inued operatio ns are as foll ows: (Rs in Mill ion) Particulars For t he period end ed For th e period end ed Se ptemb e r 30, 202 6 Se pte mber 30 , 20 25 A. Cash flow fro m Operati ng Activities Profit fo r the per iod f rom con ti nui ng operati ons 12,7 78 9,47 7 Pr ofit fo r t he pedo d fr om di scon tin ued ope rat io ns (79) (127) Adju stmen t s fo r: Depreoet ton and amort isation expense 4,526 4,325 (Prori[)/l oss on sale or property, plant&. equipment 43 (14) Profit on sale of invest ments (net} (85) (82 ) Share or (profit)/lo ss of associates (253) (199) Income tex expense 4,371 3,223 Finance costs 2,22 1 2,179 Interest income (313) (426) Dividend Income (2) (17 ) Expected credit loss on trade receivables 576 507 Provisi on written back (68) (1) Gain on fair valuatfon or mu tual funds (293) (52 5) Gain on fair vatuat(on of existing Interest of a join t venture pursuant to acquisition of control (11) Loss /(ga in) on fair valuat ion of equily Investments (3) 36 Share·based compensation expense 616 593 Gain on term inati on of lease (18 3) Operating cash fl ow before wo rking capital changes 23.85 2 18 ,938 (In crease )/ decrea se In oper ating asset s Inventories (849) (241) Trade receivables (8,571 ) (4,943) Other flnanclal assets (598) (85) Other assets (891) 273 Contract assets (214) (65 (11, 123) (5,06 1'. I ncrease/(de cr eas c) in operating liabilit ies Trade payables 6,011 801 Other financ ial llabllltles 809 900 Provisions (372) 187 Other ll.1bll1tles 82 245 6,5 30 2 ,133 Cash generated fr om operatio ns 19.259 16 ,01 0 Net income tax paid (4,326) (2,7 57) A. Net cash gene rate d f rom operatin g acti vi ti es (A) 14,9 33 13,253 B. Cash fl ow fro m I nvesti ng Activities Purchase or Property, plant and equipment, capita l work·in·prog ress and intangibles (11,999) (7,065) Proceeds from sale of property , plant and equipm ent 43 107 Proceeds from / {Investment) In bank deposits (3,0 14) 67 Purchase of Investments In subsidlarf es (3) (174) Purchase of non current inves tme nts (28) (11 ) Purchase of current Investments (9,195) (9,495 ) Proceeds from sale of current inves tments 9,649 5,644 Loans give n (33 3) Repayments received towards loans 51 254 Interest received 275 290 Dividend Receiv ed 83 17 8. Net cash used In lnv cstlng activ ities (B) (14 ,138) (1 0 ,69 9) c . Cash flow fr om f inancing activ itie s Proceeds from Issue of equity instruments by a subsidiary company 63 13 Proceeds from borrowings 2,409 1,382 Repayment or bor rowings (1,213 ) (7 46) Flnance costs (1,175) (1,305) Dividend paid on equity shares (1,438 ) (1,43 8) Dividend paid by subsidiary to Non Controllin g Interest (66) (52) Payment towards lease llablllty (1,530) (1,33 8) C. Net cas h used in fin ancing activiti es ( C) 12,95 0 ) (3,48 4 1 Net increase In cash and cash equivale nt s (A +B+C) = (0 ) (2 ,155 ) (930 ) Cash and cash equiv alents at the beginning of the period (E) 8,113 5,781 Add:Cash balance in aquired entity 33 Less: Gash and cash equivalents rcclasslflcd as hcld·for ·sale (84) Cash and cash equivalents at the end of the period (D) +(E) 5,87 4 4,884 Cash and cash equivalents compri ses or • Cash on hand 121 125 • Balance with banks 5,753 4,759 Total cash and cash equivalents at the end of the period 5,87 4 4,88 4 Stateme nt of consolidated cash flows Anne xur e II I Apollo Hospit als Ent erpri se Limite d Corpo rate I denti ty Number : L85110T N197 9P LC008 03 5 Regd. Office: No. 19 Bishop Gardens, RaJa Annamalarpuram, Chennai-28, Tamil Nadu Tel No. 44·28290956, Fax+ 91·44·282 90956, Emall : investor.relaUons@apollohospitats.com Website: www.apoltohospltals.com
Page 15
For APOLLO HO~ ISE LTD SUNEETAREOOY ~ Managing Director 3. The Board at its meeting held on June 30, 2025, subject to necessary appro vals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limit ed ("Transferor Company 1" or "AHL") - Keimed Private Limit ed ("Transferor Company 2"), and Apollo Health tech Limited ("Resulta nt Compan y") and their respec tive shareho lders and creditors ("Scheme"), in accordance with the p rovisions of Sectio ns 230-2 32 and othe r applicab le provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/ HO/ CFD/ POD- 2/ P/CIR/ 2023/93), and other applicable rules, regulations, and circulars issued by regulatory authoriti es. The Scheme inter alia provi des for demerge r of identifi ed business undert aking (as defined in the scheme) primarily represent ing the Omni channel pharm acy distr ibut ion business and digit al health platf orm business of the Company into the Resultant Company; the amal gamation of "Transferor Company 1" with and into the Result ant Company; the ama lgamation of "Transferor Company 2" with and into the Result ant Company; and the consequent listing of the equity shares of the Resultant Company on the Natio nal Stock Exchange of India Limit ed and Bombay Stoc k Exchange Limited and admission to trading . National Stock Exchange of Ind ia Limited and Bombay Stock Exchange Limited have issued lette rs dat ed December 23, 2025 and Decembe r 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Require ments) Regulations, 2015. Based on the direction s of the Hon'ble Compan y Law Tribunal , meetin gs of the Secured Creditors, Unsecured Creditor s and the Equit y Shareholders of the Company were convened on June 24, 2026 with requisite approvals being obtained for impl ement atio n of the Scheme and status being updated to the Company Law Tribunal . Subsequent to the receipt of such appro vals, the Company has filed a petition before the National Company Law Tribunal seeki ng sanction of the scheme. 2. The consolidated unaudited financial result s have been p repared in accordance wit h the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requireme nts) Regulations, 2015. 1. The consolidated unaudited financial results ("the statemen t") of Apollo Hosp itals Enterprise Limited ("the Company") for the three and six month s ended Septembe r 30, 2026 have been reviewe d by the Audit Comm ittee and appr oved by the Board of Directors of the Company at their meetings held on Novemb er 3, 2026 a nd Novem ber 4, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have exp ressed an unmodified review conclusion on the conso lidated financial results for the three and six months ended Sept ember 30, 2026 . NOTES TO THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS : Apollo Hospitals Enterprise Limited Corporat e Identity Number: L85110TN1979P LC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipura m, Chennai - 28, Tamil Nadu Tel No. 44-282 90956 , Fax+ 91-44- 282 90956, Email : investor.relations@apol lohospitals.com Website: www .apollo hospitals.com
Page 16
F APOLLO HOSPl1 LS ENTERPRISE LTD or ~~ S NEETA REDDY Managing Director 5. The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company. 6. On November 21, 2025 , the Govern ment of India notified provisions or the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Secur ity , 2020 and the Occupatio nal Safety, Health and Working Conditions Code, 2020 , ('Labour Codes') which consolidat e twe nty nine existing labour laws into a unified framework govern ing e mployee benefits during emp loyme nt and post employment . The Group has assessed the financial impli cation s of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs 192 million for the year ended March 31,2026 . Considering the mater iality and regulatory- driven n on-recurring nature of this impact, the Group has presented the same as Except ional It ems in the statem ent. The Group continues to monitor the finalisation of Central and State Rules, as well as Government clarific ations on other aspect s of the Labour Codes, and will incor porate appro priate accounting treatment based on these developments as requir ed. 7. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-comp liance with certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matt er. The Revenue Departme nt had issued a show cause not ice dat ed February 9, 2022 seeking explanations as to why the o riginal order should be withdrawn , for which the subsidiary had filed a detailed response explaining that there were no violations of the conditions relatin g to the allotment of land. During the previou s year ended March 31, 2026, the Revenue Departm ent passed an order dat ed February 13, 2026 cancelling the grant order, alleging that the land had been alienated b y the subsidiary on account of share purchase by its holding company. The subsidiary has challenged the said order before the Honour able High Court of Karnataka . The Honourable High Court of Karnataka has grant ed an interim stay on April 10, 2026 against the cancellation order and has directed the Revenu e Departme nt to file its objection s. Based on external legal opinio ns received, including opinions support ing that transf er of shares does not constitute tran sfer, alienation or sub-lease of immo vable property owned by the subsidiary, the group believes that it has adequate grounds to demonstrate compliance with the applicable conditions of the land grant. Accordingly, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefor e is of the opinion that the matt er would b e settled in its favour. 4. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to estab lish a framewo rk of rights and restriction s pursuant to which each party shall: (i) independent ly pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effec tiveness of the Scheme, the right s and obligat ions of AHL under this agreement will be binding on the Resultant Company. Apollo Hospitals Enterprise Limited Corporate Identity Number : L85110TN1979PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-28290956, Fax+ 91-44-282 90956, Email : investor .relations@apollohospitals.com Website: www .apollohospita ls.com
Page 17
For APOLLO HOSPITALS ENTERPRISE LTD ~ 4tf Managinq o;,ector Dr. Prat hap C Reddy Executive Chairman Place: Chennai Date: November 4, 2026 For APOLLO HOSPITALS ENTERPR ISE LIMITED 10. The aforesa id unaud ited financial results are also available on the Compan y's webs ite (www.apollohosp itals .com). 9. The consolidated balance sheet as at September 30, 2026 and the statement of consolidated cash flows for the six months period ended September 30, 2026 are prov ided as annexure to this stateme nt Consequent to the discontinu ed operation s, the a mounts presented in the comparat ive periods in the state ment of consolidate d unaudited fina ncial results have been represented to conform to the current period classification. Partic ulars Three Preceding Corresponding Year to date Year to date Previous months three month s three months figures for figures for year ended ended ended ended period ended period ended 31/ 03/2026 30/09 /2026 30/ 06/ 2026 30/09 / 2025 30/09/2026 30/ 09/2025 Total income 1,426 1,125 1,150 2,551 2,227 4,595 Total expenses 1,377 1,215 1,216 2,592 2,354 4,703 Profit/ (Loss) 49 (90) (66) (41) (127) (108) before tax Tax expenses (38) - - (38) - (14) Profit / Loss 11 (90) (66) (79) (127 ) (122) aft er tax The results of discontinu ed operatio ns are as below: 8. The Apollo Health and Lifestyle Limited ("AHLL"), a wholl y owned subsidiary of the Company, had planned to divest its stake in its subsidiaries, namely Apollo Specialty Hospital s Private Limited ("ASPL") and Apollo Fertility Centre Private Limit ed ("AFCPL"), to Kids Clinic India Limit ed. The tr ansaction h as been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and receive d the a pproval from the Competition Commi ssion of India (CCI) on Septem ber 1, 2026 . Further on October 12, 2026, AHLL completed the divest ment of the afores aid subsidiaries. Accordin gly, under Ind-AS 105, the Company had identified the assets and liabilities relating to ASPL and AFCPL as disposal group and classified the respective business as discontinued operations. The assets and liabilities relating to the discontinued operati ons have been disclosed a s asset held for sale and liabilities relat ing to assets held for sale as of September 30, 2026 . Apollo Hospitals Enterpr ise Limited Corporate Identity Number : L85110TN1979PLC008035 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel No. 44-2829 0956, Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com Website: www .apollo hospitals.com
Page 18
Regd. Office: One International Center, Tower 3, 31st floor, Senapati Ba pat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 Name of the Company Relationship Apollo Hospitals Enterprise Limited (AHEL) Parent Apollo Horne Healthcare Limited (AHHL) Subsidiary AB Medical Centres Limited Subsidiary Samudra Health Care Enterprises Limited Subsidiary 4. The Statement includes the results of the following entities : We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that . might be identified in an audit. Accordingly, we do not express an audit opinion. 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Apollo Hospitals Enterprise Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income (net) of its associates and joint ventures for the three months and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS Tel: +91 44 6688 5000 Chartered Accountants ASV Ramana Tower 52, Venkatnarayana Road T. Nagar Chennai-600 017 Tamil Nadu, India Deloitte Haskins & Sells LLP
Page 19
Name of the Company Relationship Imperial Hospitals & Research Centre Limited (IHRCL) Subsidiary Belenus Champion Hospitals Limited (w.e.f 2 February 2026) Subsidiary of IHRCL Apollo Hospitals (UK) Limited Subsidiary Apollo Health and Lifestyle Limited (AHLL) Subsidiary Alliance Dental Care Limited Subsidiary of AHLL Apollo Diaiysis Private Limited Subsidiary of AHLL Apollo Sugar Clinics Limited Subsidiary of AHLL Apollo Speciality Hospitals Limited Subsidiary of AHLL AHLL Diagnostics Limited Subsidiary of AHLL AHLL Risk Management Private Limited Subsidiary of AHLL Care Diagnostics Private Limited (w.e.f.1 February 2026) Subsidiary of AHLL Apollo Dialysis Philippines Inc. Subsidiary of AHLL Apollo Fertility Centre Private Limited (Formerly known as Stepdown Subsidiary Surya Fertility Centre Private Limited) of AHLL Apollo Spectra Centres Private Limited (Formerly known as Stepdown Subsidiary Kshema Healthcare Private Limited) of AHLL Apollo Cradle and Children Hospital Private Limited Stepdown Subsidiary of AHLL Apollo Nellore Hospital Limited Subsidiary Sapien Bio-sciences Private Limited Subsidiary Apollo Hospitals International Limited (AHIL) Subsidiary Apollo CVHF Limited Subsidiary of AHIL Apollo Lavasa Health Corporation Limited Subsidiary Apollo Rajshree Hospital Private Limited (ARHPL) Subsidiary Sobhagya Hospital and Research Centre Private Limited Subsidiary of ARHPL Future Parking Private Limited Subsidiary Total Health Subsidiary Apollo Hospitals Singapore Pte Limited Subsidiary Assam Hospitals Limited (Assam) Subsidiary Asclepius Hospitals and Healthcare Private Limited Subsidiary of Assam Apollomedics International Lifesciences Limited Subsidiary Apollo Multi Specialty Hospitals Limited (AMSHL) Subsidiary Apollo HealthCo Limited (AHL) Subsidiary Apollo 24/7 Insurance Services Limited Subsidiary of AHL Apollo Consumer Products Limited (w.e.f 31 March 2026) Subsidiary of AHL Apollo Medical Private Limited (AMPL) Associate of AHL Apollo Pharmacies Limited Subsidiary of AMPL Apollo Pharmalogistics Private Limited Subsidiary of AMPL Apollo Pharma Products Pvt Limited Subsidiary of AMPL Apollo Hospitals North Limited Subsidiary Kerala First Health Services Private Limited (KFHS) Subsidiary Deloitte Haskins & Sells LLP
Page 20
7. We did not review the interim financial results/financial information of 28 subsidiaries included in the consolidated unaud ited financial results, whose interim financial results/financial information reflect total assets of Rs. 44,753 million as at September 30, 2026 and, total revenues of Rs. 6,306 million and Rs. 11,982 million for the three months and six months ended September 30, 2026 respectively, total net profit after tax of Rs. 193 million and Rs. 648 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 197 million and Rs. 651 million for the three and six months ended September 30, 2026 respectively and net cash outflows of Rs. 1,394 million for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 124 million and Rs. 254 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 122 million and Rs. 257 million for the three months and 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We draw attention to Note 7 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter. Name of the Company Relationship Baalayam Healthcare Private Limited Subsidiary of KFHS Health Axis Private Limited (HAPL) Subsidiary Apollo Health Axis Inc (w.e.f 12 November 2025) Subsidiary of HAPL Opstronomy Health Technologies Private Limited (w.e.f. 17 Subsidiary of HAPL June 2026) Nexify Health Private Limited Joint venture of HAPL Apollo Hospitals Jammu and Kashmir Limited Subsidiary Apollo Hospitals Worli LLP Subsidiary Apollo Healthtech Limited (w.e.f. 10 June 2025) Subsidiary Apollo Gleneagles PET-CT Private Limited (w.e.f 30 Subsidiary September 2025) Family Health Plan Insurance (TPA) Limited Associate Indraprastha Medical Corporation Limited Associate Stemcyte India Therapeutics Private Limited Associate ApoKos Rehab Private Limited Joint venture Deloitte Haskins & Sells LLP
Page 21
Place: Chennai Date: November 4, 2026 p..J v-- t~1 . Nachiappan Subramanian Partner Membership No. 218727 UDIN: 262187270YFHXM3648 For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018) Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results/financial information certified by the Management. 8. The consolidated unaudited financial results includes the interim financial results/financial information of 9 subsidiaries which have not been reviewed by their auditors, whose interim financial results/financial information reflect total assets of Rs. 720 million as at September 30, 2026 and, total revenue of Rs. 60 million and Rs. 106 million for the three months and six months ended September 30, 2026 respectively, total net profit after tax of Rs. 17 million and Rs. 28 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 15 million and Rs. 25 million for the three months and six months ended September 30, 2026 respectively and net cash outflows of Rs. 16 million for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited financial information also includes the Group's share of loss after tax of Rs. 12 million and Rs. 13 million for the three months and six months ended September 30, 2026 respectively and total comprehensive loss of Rs. 12 million and Rs. 13 million for the three months and six months ended September 30, 2026 respectively, as considered in the Statement, in respect of 2 associates, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results/financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of these matters. six months ended September 30, 2026 respectively, as considered in the Statement, in respect of 1 joint ventures and 5 associates (including 3 subsidiaries of 1 associate), whose interim financial results/financial information have not been reviewed by us. These interim financial results/financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Deloitte Haskins & Sells LLP
Page 22
Tel : 044 - 28290956 / 3896 I 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohosp Website : www.apollohospitals.com General Office : "Ali Towers" Ill Floor, #55. Greams Road, Chennai - 600 006. Regd. Office : 19, Bishop Gardens. Raja Annamalaipuram, Chennai - 600 028. IS/ISO 9001 : 2000 SI.No Par ticular s Detai ls 1 Name of the Senior Management Dr. Madhu Sasidhar Personnel 2 Reason for change Cessation from the position of President & CEO - Hospitals Division consequent to the successf ul comp letion of his emplo yment tenure 3 Date of Cessat ion With effect from the closure of business hours on November 14, 2026 4 Brief profile (in case of appointment) Not Applicable 5 Disclosure of r elationships between Not Applicable director s Anne xur e - B CIN: L85110TN1979PLC008035 1, fAollo ~ OSPITALS APOLLO HOSPITALS ENTERPRISE LIMITED
Page 23
General Office : "Ali Towers" Ill Floor, #55, Greams Road, Chennai - 600 006. Regd. Office : 19, Bishop Gardens. Raja Annamalaipuram, Chennai - 600 028. Dr. Venkatesan holds a Ph.D. in Hospital Supply Chain Management and an MBA in Systems and brings over 25 years of diverse experience across healthcare procure ment, supply chain, pharm acy operation s, materials management , comm ercial functions, and hospital proj ect execution. Prior to jo ining Apollo, he was with Max Healt hcare Institute Ltd., New Delhi, where he served as Director & Chief Procurement Officer from August 2021. In this role, he led the group's procurement and supply chain functions across pharmacy, medical and Designat ed as Senior Management Personnel with effect from 4th November 2026 Designated as Senior Management Personnel IS/ISO 9001 : 2000 4 In his most recent role as President, Global Services at VLCC Ltd., he was responsible for str ategy & innovation, revenue & profitab ility, He holds a M aster s in Business Management fr om Neville Wadi a Institu te of Management Studies & Research, University of Pune. Date of Appointment 3 telecom, beauty and consumer services, education, wellness services. Anand has over 26 years of leadership experience building, scaling and transforming large service businesses across healthcare, financial Designated as Senior Management Personnel with eff ect from 4th Novembe r 2026 Designated as Senior Managemen t Personnel Dr. Ritu Garg has a ext ensive and diverse work experience in th e healthcare industry having held leadership roles in companies such as Fortis Healthcare, Fortis Memorial Research Institut e, and Fortis Lafemm e Limited. She has been Chief Growth & Innovation Offic er, Zonal Director and Board Member. In addition , she has also been involved in starting and co-founding initiatives such as Doctopinion.com and Healdadd y.com. Dr Ritu has also work ed as a Principal Consultant at Amrop India, where she focused on healthcar e a nd Designated a s Senior Management Personnel with eff ect from 4th November 2026 Designated as Senior Management Personnel Reason for change 2 Dr. N. Venkatesan Chief Procurement Officer Details Name of the Senior Manageme nt Personnel 1 n 0 Particulars Mr . Anand Wasker Chief Business Officer, Internat ional Details Dr. Ritu Garg, Chief Executive Officer, Multi Region (North , Centra l, Western and Eastern ) Details Brief profile (in case of appointment) s Annexure - C 1, {l'bllo ~ SPITALS CIN: L85110TN1979PLC008035 APOLLO HOSPITALS ENTERPRISE LIMITED
Page 24
Tel : 044 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohosp Website : www.apollohospitals.com General Office : "Ali Towers" Ill Floor, #55. Greams Road. Chennai - 600 006. Regd. Office : 19, Bishop Gardens. Raja Annamalaipuram, Chennai - 600 028. Not applicable IS/ISO 9001 : 2000 non-medical consumables, medical and non-medical equipment, service contr acts, and upcoming hospital projects. His responsibilities included strateg ic sourcing, cost optimisation, vendor negotiations, procurement planning, budgetin g for new hospita l construction, due diligence for acquisitions, MIS and P&L reviews, and setting up pharmac y, stores, and purchase functions for new hospitals. Not applicable operatio ns & customer service, marketing & strate gic alliances, network expansion, people develo pment & compl iance across In dia, Middle East & South Asia. of Not applicable between Dr. Ritu Garg completed her education with an MBA in Finance and Strategy fro m the Indian School of Business in 2009. Prior to that, she pursued a degree in M.B.B.S and M.S in ENT fro m Delhi University life sciences. Dr. Garg has expertise in strategy development, medical programs, clinica l talent management, and medical alliances . She has demonstrated a stron g ability to drive growt h and innovation, develop business plans, and improve busin ess perform a nee. 5 Disclosure relationships directors 1, {J'Ollo ~ OSPITALS CIN: L85110TN1979PLC008035 APOLLO HOSPITALS ENTERPRISE LIMITED
Page 25
Of this 1280 total beds and 1000 Operating I Census beds, 520 operating beds have now been commissioned, and the balance will be commissioned over the next 12 months. • Apollo continues to ramp up operations at its newly commissioned hospitals in : - Swargate - Pune - 400 beds (Phase 1 &2) - Financial District - Hyderabad - 400 beds - Defence colony - Delhi - 30 beds - Sonarpur - Kolkata - 265 beds - Sarjapur - Bengaluru - 185 beds • International Patient Services revenue grew 37% YoY in Q2 FY27, reinforcing Apollo's position as a preferred global healthcare destination. • Revenue growth driven by Robust volume increase in Congo Specialties and high Complexity Clinical work aided by key specialties like Oncology (28% growth), Gastro (27%), Cardiac and Ortho (20%) and Urology (26%). • Apollo Hospital 's expansion programme is on track to add - 5,800 beds over the next five years. • Gurugram facility with -470 beds remain on track for commissioning in Q3 FY27. • Q2 FY27 Apollo HealthCo reported revenue of Rs. 3,286 Crore and EBITDA of Rs. 193 Crore. • Q2 FY27 Apollo Health and Lifestyle Limited revenue at Rs. 429 Crore, grew 20% VoV; EBITDA at Rs. 61 crore. • Q2 FY27 Healthcare Services revenue at Rs. 3,900 Crore, grew 23% VoV; EBITDA at Rs. 937 crore. Hl FY27 Consolidated Revenue grew 22% YoY to Rs. 14,547 Crore Hl FY27 Consolidated EBITDA grew 29% YoY to Rs. 2,268 Crore Hl FY27 Consolidated PAT grew 33% YoY to Rs. 1,211 Crore Q2 FY27 Consolidated Revenue grew 23% YoY to Rs. 7,615 Crore Q2 FY27 Consolidated EBITDA grew 29% YoY to Rs. 1,191 Crore Q2 FY27 Consolidated PAT grew 32% YoY to Rs. 630 Crore Apollo Hospitals Q2FY27 Results November 4, 2026 Apollo Hospitals Q2FY27 Results Q2 FY27 Consolidated Revenue grew 23% YoY to Rs. 7,615 Crore Q2 FY27 Consolidated EBITDA grew 29% YoY to Rs. 1,191 Crore Q2 FY27 Consolidated PAT grew 32% YoY to Rs. 630 Crore H1 FY27 Consolidated Revenue grew 22% YoY to Rs. 14,547 Crore H1 FY27 Consolidated EBITDA grew 29% YoY to Rs. 2,268 Crore H1 FY27 Consolidated PAT grew 33% YoY to Rs. 1,211 Crore Q2 FY27 Healthcare Services revenue at Rs. 3,900 Crore, grew 23% YoY; EBITDA at Rs. 937 crore. Q2 FY27 Apollo Health and Lifestyle Limited revenue at Rs. 429 Crore, grew 20% YoY; EBITDA at Rs. 61 crore. Q2 FY27 Apollo HealthCo reported revenue of Rs. 3,286 Crore and EBITDA of Rs. 193 Crore. Apollo Hospital’s expansion programme is on track to add ~ 5,800 beds over the next five years. Gurugram facility with ~470 beds remain on track for commissioning in Q3 FY27. Revenue growth driven by Robust volume increase in Congo Specialties and high Complexity Clinical work aided by key specialties like Oncology (28% growth), Gastro (27%), Cardiac and Ortho (20%) and Urology (26%). International Patient Services revenue grew 37% YoY in Q2 FY27, reinforcing Apollo’s position as a preferred global healthcare destination. Apollo continues to ramp up operations at its newly commissioned hospitals in : - Swargate – Pune ~ 400 beds (Phase 1 &2) - Financial District – Hyderabad ~ 400 beds - Defence colony – Delhi ~ 30 beds - Sonarpur - Kolkata ~ 265 beds - Sarjapur – Bengaluru ~ 185 beds Of this 1280 total beds and 1000 Operating / Census beds, 520 operating beds have now been commissioned, and the balance will be commissioned over the next 12 months.
Page 26
6. Regenerative Urology: Apollo Medics Hospitals, Lucknow, performed endoscopic implantation of tissue engineered autologous buccal mucosal cells for a long-segment urethral stricture, offering a minimally invasive regenerative alternative to open surgery. 5. Advanced Stroke Care: Apollo Hospitals, Jayanagar, performed mechanical thrombectomy in a 72-year old man with Gerstmann syndrome and an MRI-negative acute ischaemic stroke after identifying a middle cerebral artery cortical branch occlusion. Successful recanalisation resulted in complete reversal of neurological deficits. 4. Advanced Gastrointestinal Care: Apollo Hospitals, Narendrapur, Kolkata, successfully performed its first Per-Oral Endoscopic Myotomy (POEM) procedure for achalasia cardia, expanding access to advanced minimally invasive treatment. 3. Technology-enabled Emergency Care: Apollo Hospitals, Visakhapatnam, inaugurated an advanced Command Centre connecting hospital specialists with smart ambulances, tele-ECG services across more than 15 peripheral nursing homes and telemedicine capabilities, strengthening emergency and cardiac care delivery. 2. Transplant Excellence: Apollo Hospitals, Greams Road, Chennai, successfully performed bilateral lung transplantation in a 41-year-old woman with end-stage lung disease after 119 consecutive days on VV-ECMO, using a single oxygenator without circuit exchange throughout the bridge to transplantation . 1. Robotic Surgery: Apollo Hospitals, Greams Road, Chennai, crossed 2,000 cumulative robotic-assisted orthopaedic surgeries across knee and hip replacements. During Q2 FY27, Apollo Hospitals continued to advance its clinical capabilities, achieving significant milestones in robotic surgery, transplantation, specialised care and technology-enabled healthcare. KEY CLINICAL HIGHLIGHTS KEY CLINICAL HIGHLIGHTS During Q2 FY27, Apollo Hospitals continued to advance its clinical capabilities, achieving significant milestones in robotic surgery, transplantation, specialised care and technology-enabled healthcare. 1. Robotic Surgery: Apollo Hospitals, Greams Road, Chennai, crossed 2,000 cumulative robotic-assisted orthopaedic surgeries across knee and hip replacements. 2. Transplant Excellence: Apollo Hospitals, Greams Road, Chennai, successfully performed bilateral lung transplantation in a 41-year-old woman with end-stage lung disease after 119 consecutive days on VV-ECMO, using a single oxygenator without circuit exchange throughout the bridge to transplantation. 3. Technology-enabled Emergency Care: Apollo Hospitals, Visakhapatnam, inaugurated an advanced Command Centre connecting hospital specialists with smart ambulances, tele-ECG services across more than 15 peripheral nursing homes and telemedicine capabilities, strengthening emergency and cardiac care delivery. 4. Advanced Gastrointestinal Care: Apollo Hospitals, Narendrapur, Kolkata, successfully performed its first Per-Oral Endoscopic Myotomy (POEM) procedure for achalasia cardia, expanding access to advanced minimally invasive treatment. 5. Advanced Stroke Care: Apollo Hospitals, Jayanagar, performed mechanical thrombectomy in a 72-year-old man with Gerstmann syndrome and an MRI-negative acute ischaemic stroke after identifying a middle cerebral artery cortical branch occlusion. Successful recanalisation resulted in complete reversal of neurological deficits. 6. Regenerative Urology: Apollo Medics Hospitals, Lucknow, performed endoscopic implantation of tissue-engineered autologous buccal mucosal cells for a long-segment urethral stricture, offering a minimally invasive regenerative alternative to open surgery.
Page 27
"The performance in this Quarter was supported by the revenue growth driven by robust volume increase in Congo T Specialties. I am encouraged by the progress we are making across our businesses and the contribution each one of our hospitals are making to the Group. India's healthcare needs are changing. People are living longer, medical conditions are becoming more complex, and the need for specialised care is growing. We must prepare for these needs well in advance. This means investing not only in hospitals and technology, but also in doctors, nurses and allied health professionals. Equally important is the ability to identify illness earlier and ensure that patients receive continuous care. Ultimately, the strength of a healthcare institution is measured by the quality of care it provides and the trust it earns from patients and their families . We are in an important phase of investment for Apollo. We must continue to build on the strength of our established businesses while developing the hospitals , clinical programmes and services that will serve patients in the years ahead. Our expansion programme, which includes plans to add - 5,800 beds over the next five years, is guided by this long-term responsibility . We are progressing with the ramp-up of our hospitals at Financial District, Hyderabad; Sonarpur , Kolkata; and Sarjapur , Bengaluru, which was commissioned in Ql FY27. Our Gurugram facility remains on track for commissioning in Q3 FY27. Building a hospital is only the beginning. What matters is the strength of its clinical teams, the range and quality of specialised services it can provide, and the confidence it builds among the people it serves . Our focus is on ensuring that each of these hospitals develops into a dependable centre of care for its community . During Q2, we also took forward our Always Open, Always Here initiative , extending routine and planned services to Sundays, subject to local schedules and service readiness. For many working people and families , finding time for a consultation or health check is not always easy. We must recognise these practical barriers and make it simpler for people to seek care . Preventive healthcare begins with making access easier. Alongside our diagnostics, pharmacies and digital platforms, this initiative gives us more opportunities to reach people earlier and support them through their healthcare journey. As we enter H2 FY27, our attention is on execution: improving operating performance, supporting the development of our newer hospitals and maintaining discipline in the way we allocate capital. I have always believed that India's healthcare sector has enormous potential but realising it requires institutions to think long term and invest responsibly. When I founded Apollo, my belief was that the people of India deserved access to the finest medical care. Over the years, we have built the experience, people and capabilities to take that vision further. Our responsibility now is to ensure that this progress translates into timely, compassionate and dependable care for more families." Dr. Prathap C. Reddy, Founder & Chairman, Apollo Hospitals Group, said: Dr. Prathap C. Reddy, Founder & Chairman, Apollo Hospitals Group, said: “The performance in this Quarter was supported by the revenue growth driven by robust volume increase in Congo T Specialties. I am encouraged by the progress we are making across our businesses and the contribution each one of our hospitals are making to the Group. India’s healthcare needs are changing. People are living longer, medical conditions are becoming more complex, and the need for specialised care is growing. We must prepare for these needs well in advance. This means investing not only in hospitals and technology, but also in doctors, nurses and allied health professionals. Equally important is the ability to identify illness earlier and ensure that patients receive continuous care. Ultimately, the strength of a healthcare institution is measured by the quality of care it provides and the trust it earns from patients and their families. We are in an important phase of investment for Apollo. We must continue to build on the strength of our established businesses while developing the hospitals, clinical programmes and services that will serve patients in the years ahead. Our expansion programme, which includes plans to add ~ 5,800 beds over the next five years, is guided by this long-term responsibility. We are progressing with the ramp-up of our hospitals at Financial District, Hyderabad; Sonarpur, Kolkata; and Sarjapur, Bengaluru, which was commissioned in Q1 FY27. Our Gurugram facility remains on track for commissioning in Q3 FY27. Building a hospital is only the beginning. What matters is the strength of its clinical teams, the range and quality of specialised services it can provide, and the confidence it builds among the people it serves. Our focus is on ensuring that each of these hospitals develops into a dependable centre of care for its community. During Q2, we also took forward our Always Open, Always Here initiative, extending routine and planned services to Sundays, subject to local schedules and service readiness. For many working people and families, finding time for a consultation or health check is not always easy. We must recognise these practical barriers and make it simpler for people to seek care. Preventive healthcare begins with making access easier. Alongside our diagnostics, pharmacies and digital platforms, this initiative gives us more opportunities to reach people earlier and support them through their healthcare journey. As we enter H2 FY27, our attention is on execution: improving operating performance, supporting the development of our newer hospitals and maintaining discipline in the way we allocate capital. I have always believed that India's healthcare sector has enormous potential but realising it requires institutions to think long term and invest responsibly. When I founded Apollo, my belief was that the people of India deserved access to the finest medical care. Over the years, we have built the experience, people and capabilities to take that vision further. Our responsibility now is to ensure that this progress translates into timely, compassionate and dependable care for more families.”
Page 28
• Hospital occupancy at 73% in Q2 FY27, compared with 69% in Q2 FY26 • Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,880 an increase of 8% YoY • 222 net new pharmacy stores added during Q2 FY27 • Platform GMV grew 20%, while Core Segment GMV grew (27% YoY Growth): Rs 571 Crore in Q2 FY27, over Rs. 450 Crore in Q2 FY26 (excluding GST impact) Q2 FY27 Operating Highlights • Revenue at Rs. 3,286 crore vs Rs. 2,661 crore in Q2 FY26; growth of 23% YoY • EBITDA at Rs. 193 crore vs Rs. 110 crore in Q2 FY26; margin at 6% • PAT at Rs. 118 crore vs Rs. 73 crore in Q2 FY26 Apollo HealthCo Q2 FY27 Performance • Revenue at Rs. 429 crore vs Rs. 359 crore in Q2 FY26; growth of 20% YoY • EBITDA at Rs. 61 crore vs Rs. 34 crore in Q2 FY26; margin at 14% • PAT at Rs. 26 crore vs PAT loss of Rs. 4 crore in Q2 FY26 • Note: AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative period financials have been re-presented accordingly Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. Apollo Health and Lifestyle Limited Q2 FY27 Performance • Revenue at Rs. 3,900 crore vs Rs. 3,169 crore in Q2 FY26; growth of 23% YoY • EBITDA at Rs. 937 crore vs Rs. 780 crore in Q2 FY26; growth of 20% YoY; margin at 24% • PAT at Rs. 486 crore vs Rs. 408 crore in Q2 FY26; growth of 19% YoY Healthcare Services Q2 FY27 Performance • Revenue at Rs. 7,615 crore vs Rs. 6,189 crore in Q2 FY26; growth of 23% YoY • EBITDA at Rs. 1,191 crore vs Rs. 924 crore in Q2 FY26; growth of 29% YoY; margin at 16% • EBITDA includes Apollo 24/7 costs of Rs. 91 crore during the quarter, including a non-cash ESOP charge of Rs. 14 crore, compared with costs of Rs. 126 crore, including a non-cash ESOP charge of Rs. 32 crore in Q2 FY26 • Reported PAT at Rs. 630 crore vs Rs. 477 crore in Q2 FY26; growth of 32% YoY • Diluted EPS from Continuing Operations of Rs. 43.71 per share in Q2 FY27, not annualized Consolidated Q2 FY27 Performance Q2FY27 FINANCIAL PERFORMANCE Q2FY27 FINANCIAL PERFORMANCE Consolidated Q2 FY27 Performance Revenue at Rs. 7,615 crore vs Rs. 6,189 crore in Q2 FY26; growth of 23% YoY EBITDA at Rs. 1,191 crore vs Rs. 924 crore in Q2 FY26; growth of 29% YoY; margin at 16% EBITDA includes Apollo 24/7 costs of Rs. 91 crore during the quarter, including a non-cash ESOP charge of Rs. 14 crore, compared with costs of Rs. 126 crore, including a non-cash ESOP charge of Rs. 32 crore in Q2 FY26 Reported PAT at Rs. 630 crore vs Rs. 477 crore in Q2 FY26; growth of 32% YoY Diluted EPS from Continuing Operations of Rs. 43.71 per share in Q2 FY27, not annualized Healthcare Services Q2 FY27 Performance Revenue at Rs. 3,900 crore vs Rs. 3,169 crore in Q2 FY26; growth of 23% YoY EBITDA at Rs. 937 crore vs Rs. 780 crore in Q2 FY26; growth of 20% YoY; margin at 24% PAT at Rs. 486 crore vs Rs. 408 crore in Q2 FY26; growth of 19% YoY Apollo Health and Lifestyle Limited Q2 FY27 Performance Revenue at Rs. 429 crore vs Rs. 359 crore in Q2 FY26; growth of 20% YoY EBITDA at Rs. 61 crore vs Rs. 34 crore in Q2 FY26; margin at 14% PAT at Rs. 26 crore vs PAT loss of Rs. 4 crore in Q2 FY26 Note: AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. Apollo HealthCo Q2 FY27 Performance Revenue at Rs. 3,286 crore vs Rs. 2,661 crore in Q2 FY26; growth of 23% YoY EBITDA at Rs. 193 crore vs Rs. 110 crore in Q2 FY26; margin at 6% PAT at Rs. 118 crore vs Rs. 73 crore in Q2 FY26 Q2 FY27 Operating Highlights Hospital occupancy at 73% in Q2 FY27, compared with 69% in Q2 FY26 Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,880 an increase of 8% YoY 222 net new pharmacy stores added during Q2 FY27 Platform GMV grew 20%, while Core Segment GMV grew (27% YoY Growth): Rs 571 Crore in Q2 FY27, over Rs. 450 Crore in Q2 FY26 (excluding GST impact)
Page 29
• Hospital occupancy at 71% in Hl FY27, compared with 67% in Hl FY26 • Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,760 an increase of 8% YoY • 373 net new pharmacy stores added during Hl FY27 • Platform GMV grew 18% while Core segment GMV grew (24% YoY Growth): Rs 1,072 Crore in Hl FY27, over Rs. 867 Crore in Hl FY26 (excluding GST impact) Hl FY27 Operating Highlights • Revenue at Rs. 6,263 crore vs Rs. 5,132 crore in Hl FY26; growth of 22% YoY • EBITDA at Rs. 364 crore vs Rs. 204 crore in Hl FY26; margin at 6% • PAT at Rs. 220 crore vs Rs. 130 crore in Hl FY26 Apollo HealthCo Hl FY27 Performance • Revenue at Rs. 817 crore vs Rs. 687 crore in Hl FY26; growth of 19% YoY • EBITDA at Rs. 106 crore vs Rs. 58 crore in Hl FY26; margin at 13% • PAT at Rs. 26 crore vs PAT loss of Rs. 10 crore in Hl FY26 • Nole: AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative period financials have been re-presented accordingly Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. Apollo Health and Lifestyle Limited Hl FY27 Performance • Revenue at Rs. 7,467 crore vs Rs. 6,104 crore in Hl FY26; growth of 22% YoY • EBITDA at Rs. 1,798 crore vs Rs. 1,497 crore in Hl FY26; growth of 20% YoY; margin at 24% • PAT at Rs. 965 crore vs Rs. 791 crore in Hl FY26; growth of 22% YoY Healthcare Services Hl FY27 Performance • Revenue at Rs. 14,547 crore vs Rs. 11,924 crore in Hl FY26; growth of 22% YoY • EBITDA at Rs. 2,268 crore vs Rs. 1,759 crore in Hl FY26; growth of 29% YoY; margin at 16% • Apollo 24/7 costs at Rs. 182 crore, including a non-cash ESOP charge of Rs. 24 crore, compared with costs of Rs. 247 crore, including a non-cash ESOP charge of Rs. 57 crore, in Hl FY26 • Reported PAT at Rs. 1,211 crore vs Rs. 910 crore in Hl FY26; growth of 33% YoY • Diluted EPS from Continuing Operations of Rs. 84.69 per share in Hl FY27, not annualized Consolidated Hl FY27 Performance H1FY27 FINANCIAL PERFORMANCE H1FY27 FINANCIAL PERFORMANCE Consolidated H1 FY27 Performance Revenue at Rs. 14,547 crore vs Rs. 11,924 crore in H1 FY26; growth of 22% YoY EBITDA at Rs. 2,268 crore vs Rs. 1,759 crore in H1 FY26; growth of 29% YoY; margin at 16% Apollo 24/7 costs at Rs. 182 crore, including a non-cash ESOP charge of Rs. 24 crore, compared with costs of Rs. 247 crore, including a non-cash ESOP charge of Rs. 57 crore, in H1 FY26 Reported PAT at Rs. 1,211 crore vs Rs. 910 crore in H1 FY26; growth of 33% YoY Diluted EPS from Continuing Operations of Rs. 84.69 per share in H1 FY27, not annualized Healthcare Services H1 FY27 Performance Revenue at Rs. 7,467 crore vs Rs. 6,104 crore in H1 FY26; growth of 22% YoY EBITDA at Rs. 1,798 crore vs Rs. 1,497 crore in H1 FY26; growth of 20% YoY; margin at 24% PAT at Rs. 965 crore vs Rs. 791 crore in H1 FY26; growth of 22% YoY Apollo Health and Lifestyle Limited H1 FY27 Performance Revenue at Rs. 817 crore vs Rs. 687 crore in H1 FY26; growth of 19% YoY EBITDA at Rs. 106 crore vs Rs. 58 crore in H1 FY26; margin at 13% PAT at Rs. 26 crore vs PAT loss of Rs. 10 crore in H1 FY26 Note: AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. Apollo HealthCo H1 FY27 Performance Revenue at Rs. 6,263 crore vs Rs. 5,132 crore in H1 FY26; growth of 22% YoY EBITDA at Rs. 364 crore vs Rs. 204 crore in H1 FY26; margin at 6% PAT at Rs. 220 crore vs Rs. 130 crore in H1 FY26 H1 FY27 Operating Highlights Hospital occupancy at 71% in H1 FY27, compared with 67% in H1 FY26 Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,760 an increase of 8% YoY 373 net new pharmacy stores added during H1 FY27 Platform GMV grew 18% while Core segment GMV grew (24% YoY Growth): Rs 1,072 Crore in H1 FY27, over Rs. 867 Crore in H1 FY26 (excluding GST impact)
Page 30
SEGMENT WISE PERFORMANCE UPDATE Healthcare Services Hospitals As at September 30, 2026, Apollo Hospitals had 8,522 operating beds across the network, excluding AHLL and managed beds. Overall occupancy during Q2 FY27 stood at 73%, compared with 69% in Q2 FY26. Consolidated revenue from the Healthcare Services division increased by 23% to Rs. 3,900 crore in Q2 FY27, compared with Rs. 3,169 crore in Q2 FY26. EBITDA, post Ind AS 116, stood at Rs. 937 crore in Q2 FY27, compared with Rs. 780 crore in Q2 FY26, representing growth of 20% YoY. New hospitals Revenue is at Rs.135 crore in Q2FY27 and EBITDA loss of 35 crore in Q2FY27. Regional performance Tamil Nadu: Revenue grew by 19% YoY, IP volumes grew by 14% YoY, and ARPP grew by 6% YoY to Rs. 2,17,162. Average occupied beds stood at 1,436, representing occupancy of 72%, compared with 1,306 beds and occupancy of 63% in Q2 FY26. AP–Telangana: Revenue grew by 30% YoY, IP volumes grew by 22% YoY, and ARPP grew by 7% YoY to Rs. 1,98,406. Average occupied beds stood at 1,021, representing occupancy of 71%, compared with 874 beds and occupancy of 68% in Q2 FY26. Karnataka: Revenue grew by 26% YoY, IP volumes grew by 16% YoY, and ARPP grew by 11% YoY to Rs. 1,94,937. Average occupied beds stood at 614, representing occupancy of 70%, compared with 547 beds and occupancy of 70% in Q2 FY26. Eastern: Revenue grew by 17% YoY, IP volumes grew by 12% YoY, and ARPP grew by 6% YoY to Rs. 1,56,749. Average occupied beds stood at 1,527, representing occupancy of 77%, compared with 1,429 beds and occupancy of 79% in Q2 FY26. Western: Revenue grew by 31% YoY, IP volumes grew by 19% YoY, and ARPP grew by 11% YoY to Rs. 1,72,284. Average occupied beds stood at 651, representing occupancy of 67%, compared with 534 beds and occupancy of 60% in Q2 FY26. Northern: Revenue grew by 16% YoY, IP volumes grew by 6% YoY, and ARPP grew by 10% YoY to Rs. 1,77,965. Average occupied beds stood at 950, representing occupancy of 77%, compared with 866 beds and occupancy of 72% in Q2 FY26. Apollo Health and Lifestyle Limited AHLL AHLL gross revenue at Rs. 429 crore; 20% YoY growth Diagnostics revenue at Rs. 227 crore; 24% YoY growth; Spectra revenue at Rs. 84 crore; 15% YoY growth. EBITDA at Rs. 61 crore; margin at 14% Note: The Apollo Health and Lifestyle Limited (“AHLL”), a wholly owned subsidiary of the Company, had planned to divest its stake in its subsidiaries, namely Apollo Specialty Hospitals Private Limited (“ASPL”) and Apollo Fertility Centre Private Limited (“AFCPL”), to Kids Clinic India Limited. The transaction has been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and received the approval from the Competition Commission of India (CCI) on September 1, 2026. Further on October 12, 2026, AHLL completed the divestment of the aforesaid subsidiaries. Accordingly, under Ind-AS 105, the Company had identified the assets and liabilities relating to ASPL and AFCPL as disposal group and classified the respective business as discontinued operations. The assets and liabilities relating to the discontinued operations have been disclosed as asset held for sale and liabilities relating to assets held for sale as of September 30, 2026. Consequent to the discontinued operations, the amounts presented in the comparative periods in the statement of consolidated unaudited financial results have been represented to conform to the current period classification. Apollo HealthCo Offline pharmacy distribution revenue at Rs. 2,885 crore in Q2 FY27; revenue from the digital platform at Rs. 401 crore. Overall HealthCo revenue at Rs. 3,286 crore; 23% YoY growth. 222 net new stores opened during the quarter, taking the total network to 7,662 stores as at September 30, 2026. GMV of Apollo 24/7 at Rs. 615 crore in Q2 FY27; growth of 20% YoY. Average Q2 FY27 order rate of 77K per day across pharmacy, diagnostics and consultations compared with 67K per day in Q2 FY2
Page 31
EXPANSION INNOVATION AND PARTNERSHIPS During Q2 FY27, Apollo continued to advance its healthcare expansion, technology and innovation agenda through capacity creation, new models of patient access and strategic collaborations. 1. Capacity Expansion: Apollo continued to ramp up operations at its Financial District hospital in Hyderabad, Sonarpur hospital in Kolkata and Sarjapur hospital in Bengaluru, with its Gurugram facility on track for commissioning in Q3 FY27. The Group's broader expansion programme envisages adding over 5,800 beds over the next five years, strengthening its presence across key markets. 2. Always Open, Always Here: Launched on August 18, 2026, the Group-wide initiative extends routine and planned healthcare services to Sundays, including outpatient consultations, diagnostics, preventive health checks, follow-ups and scheduled procedures, improving access and convenience for patients. 3. Advancing Critical Care: Apollo Hospitals and Medtronic inaugurated an 11-bed ICU of the Future at Apollo Hospitals, Jubilee Hills, Hyderabad, on July 16, 2026. The facility integrates advanced acute-care monitoring technologies with clinical expertise, creating an environment for technology-enabled critical care and clinical innovation. 4. Research and Workforce Development: Apollo Knowledge and BITS Pilani signed an MoU on September 29, 2026, to collaborate on healthcare research, education and workforce development through joint research initiatives and work-integrated learning programmes for healthcare professionals and managers. AWARDS AND ACCOLADES Apollo Hospitals was honored with the ET Family Business Award in the Large Business category in July 2026, recognising its enduring legacy and contribution to India's healthcare sector. Apollo Hospitals and its network continued to earn recognition for clinical excellence, patient care, technology and quality during the year. Key recognitions included: 1. ET Healthcare Awards 2026: Multiple national and regional honours for Apollo ProHealth (Health & Wellness Technology), Apollo Spectra Hospitals (Laparoscopic and Short-stay Surgery), Indraprastha Apollo Hospitals, Delhi (Green Hospital), Apollo Adlux Hospital, Kochi (Critical Care) and Apollomedics, Lucknow (Critical Care). Individual honours included recognition for Dr. Rakesh Jalali (Visionary Leadership) and Dr. Jyoti Bajpai (Oncology). 2. The Week–HANSA Best Hospitals Awards 2025: Recognitions for Apollo Hospitals, Ahmedabad (Ranked No. 2), Indraprastha Apollo Hospitals, Delhi, Apollo Health City, Hyderabad, Apollo Multispeciality Hospitals, Kolkata and Apollomedics, Lucknow. 3. AHPI Excellence in Healthcare Awards 2026: Recognitions for Apollo Hospitals, Ahmedabad and Guwahati for Nursing Excellence and Digital Excellence, and Apollo Adlux Hospital, Kochi, for Excellence in Operations and Emergency Services. 4. Clinical Excellence and Medical Education: Apollo Hospitals, Bannerghatta Road and Jayanagar, Bengaluru, were recognised as ISAKOS-approved teaching centres for Orthopaedics and Sports Medicine. Apollo Hospitals, Vizag, received multiple Financial Express Healthcare Summit honours across Cardiac Care, Emergency & Critical Care, Oncology and Orthopaedics. 5. Healthcare Innovation and Technology: Apollo Hospitals, Ahmedabad, received recognition for robotic surgery at Building Bharat: The Gujarat Chapter 2026, while Apollo Sage Hospitals, Bhopal, received two honours at the CII Western Region Health Innovation Awards 2026.
Page 32
6. Other Quality and Sustainability Recognitions: Indraprastha Apollo Hospitals, Delhi, received an Honourable Mention at the IHF Awards 2025 for Healthcare Workers' Wellbeing. Apollo Hospitals, Navi Mumbai, was recognised for Sustainable Healthcare Practices, while Apollo Specialty Hospitals, Trichy, secured NABH 6th Edition Accreditation. CORPORATE SOCIAL RESPONSIBILITY During Q2 FY27, Apollo Foundation continued to advance its community healthcare and development initiatives. Apollo Foundation – Total Health reached 2.13 lakh direct beneficiaries through AHEL CSR-funded programmes, with interventions spanning mental wellbeing, healthcare services, clean drinking water and sanitation. The Foundation also expanded rural healthcare access through the inauguration of three Connected Mobile Medical Units in Meghalaya and continued its Rural Integrated Community Development Project across 10 villages in East Khasi Hills. Billion Hearts Beating Foundation reached over 2.2 lakh beneficiaries through community healthcare, senior citizen care and emergency preparedness initiatives. Community Care programmes reached over 1.8 lakh people through health camps, medicine distribution, awareness and counselling sessions, and emergency care services. Senior Citizen Care supported 17,244 beneficiaries through monthly medicines, geriatric health camps, physiotherapy, yoga and essential healthcare amenities. Additionally, 22,283 people received Basic Life Support (BLS) and First Aid training, strengthening community-level emergency preparedness. About Apollo Apollo revolutionised healthcare when Dr. Prathap Reddy opened its first hospital in Chennai in 1983. Today, Apollo is the world’s largest integrated healthcare platform. As of Sep 30, 2026, its network comprised 65 hospitals with a capacity of 10,733 census beds, 7,662 pharmacy stores, 290 primary care clinics and 2,922 diagnostic centres. Apollo continues to invest in research and innovation, introducing advanced technologies, equipment and treatment protocols to give patients access to world-class care. Apollo’s 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it. For further details, log onto: www.apollohospitals.com For Media / Investors R Krishnakumar Mayank Vaswani Apollo Hospitals Enterprise Ltd. CDR India Krishnakumar_r@apollohospitals.com mayank@cdr-india.com +91 44 2829 7840 +91 22 6645 1230 Disclaimer: Some of the statements in this document that are not historical facts are forward looking statements. These forward-looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate. These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry. Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.